title: [Treatment with pravastatin of dyslipidemia associated with diabetic nephropathy].
abstract: OBJECTIVE
  Patients with type II diabetes mellitus have an increased risk of coronary he disease. We investigated the efficacy and safety of pravastatin in the treatment of patients with diabetic nephropathy and hypercholesterolemia.
  
  
  METHODS
  In this 6-months study, 12 patients (4 men, 8 women, mean age 60.5 +/- 10.8 years), with diabetic nephropathy and hypercholesterolemia (fasting plasma low-density lipoprotein cholesterol levels -LDL-C- > 130 mg/dl) received pravastatin 10 mg/day. The dose could be doubled after 4 weeks. Seven patients have chronic renal failure.
  
  
  RESULTS
  Significant reductions in LDL-C (-19.1%, p < 0.05), total cholesterol (-16%, p < 0.01), very-low-density lipoprotein cholesterol (-29.2%, p < 0.05), apolipoprotein B (-21.5%, p < 0.05), and triglycerides (-26.0%, p < 0.01) were noted. No changes were found either in high-density-cholesterol or its fractions (HDL2 and HDL3) or in apolipoprotein A plasmatic levels. Pravastatin was well tolerated and no one side effect was detected. No clinically significant changes on the control of diabetes, renal function, as assessed by plasmatic creatinin and creatinin clearance, and proteinuria were seen during the follow-up time.
  
  
  CONCLUSIONS
  The results of the study demonstrate that pravastatin is well tolerated and effective in lowering total cholesterol and LDL-C in patients with diabetic nephropathy and hypercholesterolemia.
authors.affiliation: Sección de Nefrología, Hospital Universitario Infanta Cristina, Badajoz.
authors.forename: N R
authors.initials: NR
authors.lastname: Robles
authors.forename: R
authors.initials: R
authors.lastname: Ruiz-Calero
authors.forename: M
authors.initials: M
authors.lastname: Coronado
authors.forename: J M
authors.initials: JM
authors.lastname: Escola
authors.forename: E
authors.initials: E
authors.lastname: Sánchez Casado
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D017035:Pravastatin